Intensive Blood Pressure Management Reduces CVD Risk in Diabetic Patients: A Proven Approach
An intensive blood pressure treatment lowered the risk of cardiovascular disease in adults with type 2 diabetes. This finding comes from the Blood Pressure Control Target in Diabetes (BPROAD) Study, which involved nearly 13,000 adults in China. Researchers focused on the impact of lowering systolic blood pressure (SBP) to 120 mmHg or less.
The study examined major cardiovascular events, including non-fatal heart attacks, strokes, treated heart failure, or cardiovascular-related deaths. Guang Ning, MD, a professor at Ruijin Hospital in Shanghai, led the research. He stated that reducing SBP to below 120 mmHg significantly decreases the risk of these events for most people with type 2 diabetes.
Data shows that about 75% of adults with type 2 diabetes also have high blood pressure. It is important to manage blood pressure through lifestyle changes and medications to prevent serious cardiovascular problems.
BPROAD included 12,821 adults from 145 locations across mainland China. Participants had elevated SBP levels, defined as 140 mmHg or higher if not on medication, or 130 mmHg or higher while taking at least one antihypertensive drug. The average age of participants was 64, and nearly half were women.
What are the recommended blood pressure targets for adults with type 2 diabetes based on recent studies?
Interview with Dr. Guang Ning: Insights on Intensive Blood Pressure Treatment for Adults with Type 2 Diabetes
News Directory 3: Dr. Guang Ning, thank you for joining us today to discuss the findings of the Blood Pressure Control Target in Diabetes (BPROAD) Study. Can you briefly summarize the key takeaways from your research?
Dr. Guang Ning: Thank you for having me. The BPROAD Study involved nearly 13,000 adults in China, specifically focusing on individuals with type 2 diabetes and elevated systolic blood pressure (SBP). Our key finding was that lowering SBP to 120 mmHg or less significantly reduced the risk of major cardiovascular events, such as heart attacks and strokes. This is particularly important as approximately 75% of adults with type 2 diabetes also suffer from high blood pressure.
News Directory 3: That’s fascinating. How did you structure the study, and what were the major outcomes?
Dr. Guang Ning: We included 12,821 participants from 145 locations across mainland China. They were divided into two groups: one aimed for an SBP of 120 mmHg or less, while the other targeted 140 mmHg or less. Over the study duration, we observed 393 major cardiovascular events in the intensive treatment group compared to 492 in the standard treatment group. This clearly indicates that targeting a lower SBP can lead to a substantial decrease in cardiovascular complications.
News Directory 3: Were there any noteworthy differences in adverse events between the two groups?
Dr. Guang Ning: Yes, both groups experienced similar rates of serious adverse events; however, the intensive treatment group reported higher instances of symptomatic hypotension and hyperkalemia. It’s important for clinicians to monitor patients closely when implementing such intensive management strategies.
News Directory 3: Considering these findings, what implications do you see for future guidelines in treating patients with type 2 diabetes?
Dr. Guang Ning: I hope that clinical guidelines will reflect our findings, particularly in how blood pressure targets are set for adults with type 2 diabetes. We need to balance the benefits of intensive treatment against potential side effects. Additionally, further research is essential to identify which patients are most likely to benefit from this approach while minimizing risks.
News Directory 3: What advice would you give to healthcare providers and patients regarding blood pressure management?
Dr. Guang Ning: It’s crucial to manage blood pressure through lifestyle changes—such as diet and exercise—as well as medication. Regular monitoring is key, especially for those with type 2 diabetes, to prevent serious cardiovascular issues. Collaboration between patients and healthcare providers can lead to tailored treatment strategies that optimize health outcomes.
News Directory 3: Thank you, Dr. Ning, for sharing your insights and the important findings from the BPROAD Study with us. We appreciate your time and expertise.
Dr. Guang Ning: Thank you for the opportunity to discuss this important research.
The study split participants into two groups: one group aimed for an SBP of 120 mmHg or less, and the other aimed for 140 mmHg or less. The results showed 393 major cardiovascular events occurred in the intensive treatment group, compared to 492 in the standard group, which translates to lower rates of complications in the intensive group.
While both groups experienced similar rates of serious adverse events, the intensive group reported more cases of symptomatic hypotension and hyperkalemia. Ning noted that previous studies also indicated benefits from intensive SBP control in patients without diabetes.
Ning hopes future clinical guidelines will consider these results when setting blood pressure targets for adults with type 2 diabetes. He believes more research should identify individuals who will benefit most from intensive treatment with the least risk of side effects.